Tetsumasa Sasaoka

Summary

Country: Japan

Publications

  1. ncbi Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model
    Toshiaki Iba
    Department of Emergency and Disaster Medicine, Juntendo University, Hongo Bunkyo ku, Tokyo, 113 8421, Japan
    Crit Care 13:R203. 2009
  2. ncbi Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells
    Tetsumasa Sasaoka
    Pharmaceutical Research Laboratory, Research Division, Nihon Pharmaceutical, Co Ltd, Sumiyoshichou, Izumisano, Osaka, Japan
    Am J Physiol Gastrointest Liver Physiol 300:G568-76. 2011

Collaborators

  • Toshiaki Iba
  • Yoichi Ohno
  • Kenji Nakajima
  • Etsuro Nakarai
  • Toshio Takayama

Detail Information

Publications2

  1. ncbi Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model
    Toshiaki Iba
    Department of Emergency and Disaster Medicine, Juntendo University, Hongo Bunkyo ku, Tokyo, 113 8421, Japan
    Crit Care 13:R203. 2009
    ..Recombinant human soluble thrombomodulin (rhsTM) is newly developed for the treatment of DIC. The purpose of this study was to evaluate the efficacy of the concomitant administration of rhsTM and antithrombin (AT)...
  2. ncbi Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells
    Tetsumasa Sasaoka
    Pharmaceutical Research Laboratory, Research Division, Nihon Pharmaceutical, Co Ltd, Sumiyoshichou, Izumisano, Osaka, Japan
    Am J Physiol Gastrointest Liver Physiol 300:G568-76. 2011
    ..These results suggest new possible therapeutic approaches for IBD, including disorders such as Crohn's disease and ulcerative colitis...